DataSheet2_Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices.pdf

Introduction: The practice of informed consent (IC) for pharmacogenomic testing in clinical settings varies, and there is currently no consensus on which elements of IC to provide to patients. This study aims to assess current IC practices for pharmacogenomic testing.Methods: An online survey was developed and sent to health providers at institutions that offer clinical germline pharmacogenomic testing to assess current IC practices.Results: Forty-six completed surveys representing 43 clinical institutions offering pharmacogenomic testing were received. Thirty-two (74%) respondents obtain IC from patients with variability in elements incorporated. Results revealed that twenty-nine (67%) institutions discuss the benefits, description, and purpose of pharmacogenomic testing with patients. Less commonly discussed elements included methodology and accuracy of testing, and laboratory storage of samples.Discussion: IC practices varied widely among survey respondents. Most respondents desire the establishment of consensus IC recommendations from a trusted pharmacogenomics organization to help address these disparities.</p

DataSheet1_Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices.docx

Introduction: The practice of informed consent (IC) for pharmacogenomic testing in clinical settings varies, and there is currently no consensus on which elements of IC to provide to patients. This study aims to assess current IC practices for pharmacogenomic testing.Methods: An online survey was developed and sent to health providers at institutions that offer clinical germline pharmacogenomic testing to assess current IC practices.Results: Forty-six completed surveys representing 43 clinical institutions offering pharmacogenomic testing were received. Thirty-two (74%) respondents obtain IC from patients with variability in elements incorporated. Results revealed that twenty-nine (67%) institutions discuss the benefits, description, and purpose of pharmacogenomic testing with patients. Less commonly discussed elements included methodology and accuracy of testing, and laboratory storage of samples.Discussion: IC practices varied widely among survey respondents. Most respondents desire the establishment of consensus IC recommendations from a trusted pharmacogenomics organization to help address these disparities.</p

Relationships between resisted sprint performance and different strength and power measures in rugby players

This study aimed to investigate the relationship between a specific isometric-strength sprint test (SIST) and unresisted maximum velocity (Vmax), sprint times across different loading conditions, and the velocity loss (Vloss) loads required to achieve each intended Vloss condition during resisted sprint training (RST) in rugby players. Additionally, the investigation examined the relationship between strength in the back-squat one-repetition maximum (1RM-SQ) as well as isometric squat (ISQT), jumps, and sprint performance variables. Twenty (n = 20) male amateur rugby players performed, on two separate occasions, a structural multiple-joint assessment of jumps, strength, and sprint performance. Interestingly, SIST revealed moderate correlations (r = 0.453 to 0.681; p < 0.05) between 1RM-SQ and ISQT. The SISTrel (relative to body mass), but not SIST, used in the present study showed moderate correlations (r = 0.508 to 0.675; p < 0.05) with the loads needed to reach 10%, 30%, and 50% of Vloss during RST. The SISTrel that measures resultant force application in a more sprint-related position explains much of the individual response of each athlete during sprinting towing a sled and can also be used to prescribe and quantify loads in the RST in a more objective and individual manner